Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Taysha Gene Therapies (TSHA)
NASDAQ:TSHA
RESEARCH TOOLSreports
Holding TSHA?
Track your performance easily
TSHA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.19 - $4.32
Previous Close$3.24
Volume2.24M
Average Volume (3M)3.77M
Market Cap
$664.02M
Enterprise Value$567.04M
Total Cash (Recent Filing)$157.70M
Total Debt (Recent Filing)$60.72M
Price to Earnings (P/E)―
Beta1.35
Next Earnings
Mar 26, 2025EPS Estimate
-$0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding204,943,306
10 Day Avg. Volume8,316,892
30 Day Avg. Volume3,774,055
Standard Deviation0.60
R-Squared0.00107
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)4.67
Price to Sales (P/S)43.79
Price to Cash Flow (P/CF)-5.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue57.16
Enterprise Value/Gross Profit36.70
Enterprise Value/Ebitda-33.18
Forecast
1Y Price Target
$6.61Price Target Upside104.01% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
Taysha Gene Therapies News
PremiumCompany Announcements
Taysha Gene Therapies Advances in Rett Syndrome Trials
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentTSHA-102 in Rett syndrome could drive significant value given initial Ph 1/2 safety data validated PoC with no signs of toxic MeCP2 overexpression.
Financial PositionTSHA ended the quarter with $157.7M in cash, expected to be sufficient into 4Q26.
Regulatory AlignmentThere is already alignment with the FDA on the final commercial manufacturing process, which will be used starting in Part B.
Bears Say
Clinical Data ComparisonThe efficacy comparison is complicated due to TSHA's shorter follow-up time for its pediatric data, making it hard to compare directly with NGNE's data.
Financial PerformanceNet loss per share was ($0.10) vs. consensus of ($0.09).
Market ReactionThe selloff post data (-26%) is seen as unwarranted, with high expectations for pediatric patients potentially contributing.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
TSHA FAQ
What was Taysha Gene Therapies’s price range in the past 12 months?
Taysha Gene Therapies lowest stock price was $1.19 and its highest was $4.32 in the past 12 months.
What is Taysha Gene Therapies’s market cap?
Currently, no data Available
When is Taysha Gene Therapies’s upcoming earnings report date?
Taysha Gene Therapies’s upcoming earnings report date is Mar 26, 2025 which is in 95 days.
How were Taysha Gene Therapies’s earnings last quarter?
Taysha Gene Therapies released its earnings results on Nov 13, 2024. The company reported -$0.1 earnings per share for the quarter, missing the consensus estimate of -$0.087 by -$0.013.
Is Taysha Gene Therapies overvalued?
According to Wall Street analysts Taysha Gene Therapies’s price is currently Undervalued.
Does Taysha Gene Therapies pay dividends?
Taysha Gene Therapies does not currently pay dividends.
What is Taysha Gene Therapies’s EPS estimate?
Taysha Gene Therapies’s EPS estimate is -$0.08.
How many shares outstanding does Taysha Gene Therapies have?
Taysha Gene Therapies has 204,943,310 shares outstanding.
What happened to Taysha Gene Therapies’s price movement after its last earnings report?
Taysha Gene Therapies reported an EPS of -$0.1 in its last earnings report, missing expectations of -$0.087. Following the earnings report the stock price went up 2.715%.
Which hedge fund is a major shareholder of Taysha Gene Therapies?
Among the largest hedge funds holding Taysha Gene Therapies’s share is RA Capital Management. It holds Taysha Gene Therapies’s shares valued at 22M.
---
Taysha Gene Therapies Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$6.61 (104.01% Upside)
$6.61 (104.01% Upside)
Blogger Sentiment
Bullish
TSHA Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 28.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.0%
Last 30 Days ▼ 3.6%
Last 30 Days ▼ 3.6%
Technicals
SMA
Negative
20 days / 200 days
Momentum
78.02%
12-Months-Change
Fundamentals
Return on Equity
-114.77%
Trailing 12-Months
Asset Growth
-7.94%
Trailing 12-Months
Company Description
Taysha Gene Therapies
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. It is advancing a deep and sustainable product portfolio of 18 gene therapy product candidates, with exclusive options to acquire four additional development programs. Its product candidates include TSHA-101, TSHA-118, TSHA-102, TSHA-103, and TSHA-104.
---
TSHA Earnings Call
Q3 2024
0:00 / 0:00
---
TSHA Stock 12 Month Forecast
Average Price Target
$6.61
▲(104.01% Upside)
Technical Analysis
Best Analysts Covering TSHA
1 Year
1 Year Success Rate
10/15 ratings generated profit
1 Year Average Return
+42.78%
assigned a buy rating last month
Copying Joon Lee's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +42.78% per trade.
---